Microbot Medical Inc. Common Stock (MBOT)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Microbot Medical is a development-stage medical device company. In FY2025, the year ended 2025-12-31, filed figures show no revenue and a net loss of $13.1M; FY2024 had a $11.4M loss and FY2023 a $10.7M loss. The first half of fiscal 2026 shows only tiny revenue: $105,000 in fiscal Q1 2026, quarter ended 2026-03-31, and $241,000 in fiscal Q2 2026, quarter ended 2026-06-30, alongside net losses of $3.7M and $5.6M. Trailing twelve-month free cash flow is negative $15.4M, a FairStock calculation, so the enterprise consumes cash rather than produces it. The balance sheet has low leverage, with D/E 0.01, and a FairStock-calculated Altman Z-score of 9.39; but the Piotroski F-score is 1/9, confirming weak fundamentals. At the 2026-10-13 close of $1.02, market cap is $68.5M. FairStock calculates P/E at -4.08 and P/B at 0.99. P/B near one may look modest, but book value is largely supporting ongoing losses, not earning power. There is no demonstrated moat: no revenue scale, no profits, no pricing power. LIBERTY targets a promising endovascular robotic niche, but regulatory and commercial adoption remain unproven. Graham would say that without earning power we cannot calculate intrinsic value; we can only speculate on future cash flows. The stock is near its 52-week low of $1.01 and far below its high of $3.03. FairStock score is 37/100, and the Lynch category is none because the company lost money in each of the last four years. This is a speculative venture, not a proven compounding machine. I would want repeatable sales and much less cash burn before calling it a sound value.

In plain English: Microbot Medical is a small medical device company working on a robotic system to help doctors perform minimally invasive blood vessel procedures. The business looks weak today: it has very little revenue and has been losing money for years. Because there are no steady profits, the stock price is hard to judge by ordinary measures, though it is trading near the bottom of its 52-week range.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer